Ovid Therapeutics

Yahoo Finance • 28 days ago

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures and an open-label, pr... Full story

Yahoo Finance • 4 months ago

Promising Penny Stocks To Watch In December 2025

As the U.S. stock market continues to reach new heights, with major indices like the Dow Jones and S&P 500 setting all-time records, investors are exploring diverse opportunities across various sectors. Penny stocks, often overlooked yet i... Full story

Yahoo Finance • 4 months ago

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra... Full story

Yahoo Finance • 5 months ago

Ovid Therapeutics GAAP EPS of -$0.17 misses by $0.02, revenue of $0.13M misses by $0.04M

* Ovid Therapeutics press release [https://seekingalpha.com/pr/20303367-ovid-therapeutics-announces-planned-leadership-succession-and-reports-business-updates-and] (OVID [https://seekingalpha.com/symbol/OVID]): Q3 GAAP EPS of -$0.17 miss... Full story

Yahoo Finance • 5 months ago

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329, demonstrated strong... Full story

Yahoo Finance • 5 months ago

QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer

QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer Physician-scientist brings more than two decades of R&D leadership experience in neuroscience, rare disease, and pain modulation at organizations including Ab... Full story

Yahoo Finance • 6 months ago

Ovid spikes as Wedbush moves to Outperform on lead asset

[Wall Street sign in Lower Manhattan, NYC] georgeclerk/iStock via Getty Images Ovid Therapeutics (NASDAQ:OVID [https://seekingalpha.com/symbol/OVID]) added ~13% on Thursday after Wedbush revised its rating to Outperform from not rated, ci... Full story

Yahoo Finance • 6 months ago

Ovid rises after positive results from epilepsy study

[Doctor writing word Epilepsy with marker, Medical concept] Michail_Petrov-96/iStock via Getty Images * Ovid Therapeutics (NASDAQ:OVID [https://seekingalpha.com/symbol/OVID]) stock rose after encouraging results from its early stage stu... Full story

Yahoo Finance • 6 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 7 months ago

Mixed Catalysts Drive After-Hours Moves In MRM, LEXX, SHOT, AQST, And OVID

(RTTNews) - Several small-cap names posted sharp gains in Thursday's after-hours session, driven by fresh corporate updates, clinical developments, and strategic pivots. Below are five stocks that stood out for their notable post-close mov... Full story

Yahoo Finance • 8 months ago

Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating

Investing.com - Lucid Capital Markets initiated coverage on Ovid Therapeutics Inc (NASDAQ:OVID) with a Buy rating and a $5.50 price target on Wednesday. The target represents significant upside potential for the $38.9 million market cap co... Full story

Yahoo Finance • 9 months ago

Solvonis chair to participate in biotech leadership panel

LONDON - Solvonis Therapeutics plc (LSE:SVNS) Chairman Dennis Purcell will join a panel discussion at an investor event hosted by Lucid (NASDAQ:LCID) Capital Markets on Thursday, July 17, the clinical-stage biopharmaceutical company announ... Full story

Yahoo Finance • 10 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today... Full story

Yahoo Finance • 10 months ago

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on T... Full story

Yahoo Finance • last year

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appoin... Full story

Yahoo Finance • last year

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, Presid... Full story

Yahoo Finance • last year

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that management will parti... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for soticlestat The Company extended its expected cash runway into 2026 Clinical trials study... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously reta... Full story

Yahoo Finance • 3 years ago

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today anno... Full story